Fuse Medical snaps up second company in a year

Fuse Medical (OTC: FZMD) has completed its acquisition of Maxim Surgical, a spinal fusion device company and device distributor, for an undisclosed sum. It’s the second acquisition in the past year for Fuse, which purchased CPM Medical Consultants in December 2017. All three companies are based in Richardson, Texas. Formed in April 2011, Maxim designs and

MiMedx top brass resign amid internal accounting investigation

MiMedx CEO Parker H. “Pete” Petit and COO and President William C. “Bill” Taylor have resigned as a board-directed independent investigation continues into accounting practices, Marietta, Ga.–based MiMedx (Nasdaq: MDXG) announced today. Petit and Taylor’s exit comes after recent departures of MiMedx’s CFO and corporate controller and treasurer. In addition to the resignations of top brass, the

CEL-SCI wins $2.9M in CRO legal battle

Score one for the little guy. After a four-year legal battle, immunotherapy maker CEL-SCI Corporation has won the first-ever breach-of-contract case against a contract research organization, or CRO. In a final and binding decision, an arbitrator concluded that CRO inVentiv knowingly and fraudulently misled CEL-SCI with regard to enrollment projections for a clinical trial of

Can placental tissue implants limit back and leg pain?

Regenerative technology company StimLabs has enrolled the first patient in a clinical trial using shelf-stable placental tissue to reduce complications following herniated disc surgery. The multi-center, randomized controlled trial will evaluate the safety and efficacy of Revita, StimLabs’ full-thickness placental allograft, which surgeons will place following lumbar microdiscectomy procedures. Microdiscectomy is a common, minimally invasive procedure

How you can control lab-grown heart cells with a remote control light

University of California San Diego researchers have created a technique that speeds up and slows down human heart cells that are being grown in a dish on command by shining light on them and varying the intensity. The heart cells are being grown in graphene which turns light into electricity, a more realistic environment that

The best medtech funding option you’ve never heard of

Regulation A+ (Reg A+) is a funding option that feels tailor-made for high impact technologies like medtech. Never heard of it? That’s because it didn’t exist until 2015, when the Obama administration passed the JOBS Act. Before then, private companies could only seek backing from the wealthiest 2% of Americans — accredited investors. The new

This fluorescent dye could create clearer biological imaging

Massachusetts researchers have repurposed a commercially-available dye that has been around since the 1950s to make short-wave infrared easily available for clearer imaging. Fluorescence imaging is often used to visualize biological tissues or blood vessels during reconstructive surgery to see if vessels are connected properly. Currently, researchers use a dye that runs at the near-infrared

This tissue paper is made from actual organ tissues

Northwestern University researchers have created biomaterials made from animal organs and tissues that could potentially support natural hormone production in young cancer patients and aid wound healing. The materials, aptly named tissue papers, are made from structural proteins that are excreted by cells and give organs their forms and structures. The tissue papers are thin and

ABL increases aseptic fill/finish capacity with automated vial filling line

ABL, a leading contract research, development and biomanufacturing organization to the biopharmaceutical industry worldwide, has announced the expansion of its aseptic fill/finish operations at its Rockville, Md. GMP biomanufacturing facility with the installation of a new, fully automated vial filling system. ABL’s new filling line was specifically selected by ABL to meet the needs of

Sepsis causes most hospital readmissions

A University of Pittsburgh School of Medicine and VA Pittsburgh Healthcare System analysis recently showed that sepsis results in more hospital readmissions and costs than any of the other 4 medical conditions that the government tracks for quality of care and guide pay-for-performance reimbursements. The results should provide food for thought for medical device developers

Medtech stories we missed this week: April 28, 2017

From FDA and Health Canada approvals to joint ventures, here are medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Joimax Endovapor 2 Joimax announced in an April 26 press release that it has received FDA 510(k) clearance to market its Endovapor 2 Multi-Radio Frequency System. The device generates

This test can detect tiny ovarian tumors sooner than current tests

Massachusetts Institute of Technology engineers have developed a way to detect ovarian tumors that are smaller than 2 mm in diameter, allowing for detection 5 months earlier than existing tests. A synthetic biomarker, which is a nanoparticle that works with tumor proteins to release fragments into the urine for detection, helps the MIT-developed test create

This molecule stops pancreatic cancer cells from spreading

Wake Forest Baptist Medical Center scientists have identified molecules that could be the next therapeutic solution for pancreatic cancer. Pancreatic cancer is one of the most lethal forms of cancer. About 53,670 people are expected to be diagnosed with pancreatic cancer this year with 43,090 dying from it, according to the American Cancer Society. The

Your brain doesn’t navigate like a GPS after all

Neurons were once considered the brain’s GPS, and they were subject of a Nobel Prize in 2014 that outlined the discovery of grid cells and specialized neurons that help animals keep track of their location in environments. New Stanford University research suggests that the brain and neurons just might be more complex than that. Lisa

How the CellMist SkinGun heals: a Q&A with RenovaCare’s CEO

When Thomas Bold joined RenovaCare in 2013, he was already familiar with its potentially groundbreaking technology. Bold had served as StemCell Systems CEO in Berlin for many years. He was involved in the development of the CellMist and SkinGun – the platform technologies for RenovaCare Inc. The technologies represent a shift in thinking about wound care, Bold said. Bold’s goal